Combined Therapies for Duchenne Muscular Dystrophy to Optimize Treatment Efficacy
Open Access
- 10 April 2018
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 9, 114
Abstract
Duchene Muscular Dystrophy (DMD) is the most frequent muscular dystrophy and one of the most severe due to the absence of the dystrophin protein. Typical pathological features include muscle weakness, muscle wasting, degeneration, and inflammation. At advanced stages DMD muscles present exacerbated extracellular matrix and fat accumulation. Recent progress in therapeutic approaches has allowed new strategies to be investigated, including pharmacological, gene-based and cell-based therapies. Gene and cell-based therapies are still limited by poor targeting and low efficiency in fibrotic dystrophic muscle, therefore it is increasingly evident that future treatments will have to include “combined therapies” to reach maximal efficiency. The scope of this mini-review is to provide an overview of the current literature on such combined therapies for DMD. By “combined therapies” we mean those that include both a therapy to correct the genetic defect and an additional one to address one of the secondary pathological features of the disease. In this mini-review, we will not provide a comprehensive view of the literature on therapies for DMD, since many such reviews already exist, but we will focus on the characteristics, efficiency, and potential of such combined therapeutic strategies that have been described so far for DMD.Keywords
Funding Information
- Centre National de la Recherche Scientifique
- Institut National de la Santé et de la Recherche Médicale
- Association Française contre les Myopathies (17110)
- Université Pierre et Marie Curie
- Comisión Nacional de Investigación Científica y Tecnológica (#C16S02)
- Fondo Nacional de Desarrollo Científico y Tecnológico (1161646)
This publication has 94 references indexed in Scilit:
- Reading Frame Correction by Targeted Genome Editing Restores Dystrophin Expression in Cells From Duchenne Muscular Dystrophy PatientsMolecular Therapy, 2013
- Prednisolone Treatment Does Not Interfere with 2′- O -Methyl Phosphorothioate Antisense-Mediated Exon Skipping in Duchenne Muscular DystrophyHuman Gene Therapy, 2012
- Losartan Restores Skeletal Muscle Remodeling and Protects Against Disuse Atrophy in SarcopeniaScience Translational Medicine, 2011
- Interleukin-10 reduces the pathology of mdx muscular dystrophy by deactivating M1 macrophages and modulating macrophage phenotypeHuman Molecular Genetics, 2010
- Targeting Fibrosis in Duchenne Muscular DystrophyJournal of Neuropathology & Experimental Neurology, 2010
- Expression of Dog Microdystrophin in Mouse and Dog Muscles by Gene TherapyMolecular Therapy, 2010
- Combination of Myostatin Pathway Interference and Dystrophin Rescue Enhances Tetanic and Specific Force in Dystrophic mdx MiceMolecular Therapy, 2010
- Complete Genetic Correction of iPS Cells From Duchenne Muscular DystrophyMolecular Therapy, 2010
- Nuclear factor-kappa B signaling in skeletal muscle atrophyJournal of Molecular Medicine, 2008
- Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapyProceedings of the National Academy of Sciences, 2007